El Futuro en el Tratamiento del Cáncer Renal - page 12

First line ongoing trials
https://clinicaltrials.gov/ct2/show/NCT02853331
Atkins MB, et al. ESMO 2016
KEYNOTE 426
Phase III
Axitinib + pembro
5 mg BID + 200 mg (IV) every 3 weeks
Sunitinib
50 mg/day 4/2
Co-Primary endpoint: PFS, OS
PD-1 + VEGFR TK inhibition
R n=840